Direct link to deposited data
Raw and processed microarray data is available in GEO under accession GSE62945 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE62945.
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Study design
The identification of myostatin as a negative regulator of skeletal muscle mass raised the possibility that blocking the myostatin signaling could have important applications for treating patients with muscle degenerative diseases [1] . However, there is one theoretical concern that inducing muscle hypertrophy may cause additional membrane stress, ( causing further damage to already fragile muscle fibers. To investigate this possibility, we used both genetic and pharmacological approaches to examine the effect of blocking myostatin in dysferlin mutant (Dysf
) mice, which is a model for limb-girdle type 2B and Miyoshi muscular dystrophies. Our rationale was that if myostatin inhibition caused increased membrane damage, these effects would be enhanced in Dysf −/− mice, in which membrane repair is compromised [2] .
For the genetic approach, we used transgenic mice expressing the myostatin inhibitor, follistatin, exclusively in skeletal muscle (F66 transgenic mice) [3] , and for the pharmacological approach, we used a soluble form of the activin type IIB receptor (ACVR2B) in which the extracellular ligand binding domain was fused to an Fc domain 
Labeling and hybridization
The Ambion Expression WT kit (Thermo Fisher Scientific Inc., Waltham, MA) was used to label isolated total RNA, according to the manufacturer's manual. The labeled cDNAs were hybridized onto Affymetrix Mouse Exon 1.0 ST arrays (Affymetrix, Inc., Santa Clara, CA) for 17 h at 45°C with rotation (60 rpm) as described by Affymetrix in their GeneChip Expression Analysis Technical Manual. After washing, the arrays were scanned with Affymetrix' GeneChip Scanner 3000 7G.
Data processing
Affymetrix CEL files generated by GeneChip Command Console software were extracted and normalized using the Robust Multichip Analysis (RMA) algorithm in Partek Genomics Suite v6.6 software (Partek Inc., St. Louis, USA) [5] . To ensure exploration of the broadest range of gene transcripts, we imported all 641,130 Affymetrix "Extended Metaprobesets". Quality control assessments were run (Fig. 1) and these exon-level probesets were summarized into 115,830 transcripts, of which 34,343 currently had annotation at the gene level. As the understanding of genomics and information on the mouse genome increase these values will change over time, with the June 2015 annotation showing 47,252 gene-level transcripts.
Transcription analysis used a single expression value, determined from each transcript's exons, for transcript-level comparisons to detect differential gene expression between samples under different conditions. The one-way analysis of variance (ANOVA) was used to determine the magnitude (fold change) and statistical significance (p-value) of genes' changes in expression level between sample classes.
Data analysis
Microarray data were visualized by principal components analysis (PCA) mapping, volcano plots, and heat maps [6] . PCA analysis was performed with the Partek platform, while volcano plots and heat maps were generated with the Spotfire DecisionSite software (TIBCO Software Inc., Boston, MA). Linear regression analyses were performed with Spotfire to compare two different sets of transcriptome changes (Fig. 2) . Gene Ontology (GO; www.geneontology.org) analysis was conducted for significantly differentially expressed 763 genes (fold change N 2.0, p b 0.01 in wt versus F66;Dysf −/− ) using Spotfire's Gene Ontology Browser [7] . Canonical Pathways, Upstream Regulators, and Network analyses were generated using Ingenuity Pathway Analysis (IPA; QIAGEN Redwood City, CA, USA) and summarized in Tables 1, 2 , and 3. Myostatin is a transforming growth factor-ß (TGF-ß) family member, and as expected, TGF-ß1 was a top upstream regulator in F66 mouse muscle (versus wt) (Fig. 3) .
Conclusion
Collectively, our results demonstrated that Fst overexpression and ACVR2B/Fc administration in dysferlin mutant mice, a mouse model for limb-girdle type 2B and Miyoshi muscular dystrophies, induced the dramatic changes of gene expression profiling. Our data sets provide a resource for exploring molecular mechanisms that are related to hypertrophy-induced, accelerated muscular degeneration in dysferlinopathy.
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